skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's technology and its future. Prexton raised EUR 29 million via a series B financing earlier this year to progress foliglurax, a metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM), into Phase II trials. A European Phase II trial is expected to enroll its first patient in June and will be completed by the end of 2018. A US trial is also planned. After Phase II, Conquet hopes the company will be able to license the compound to a big pharma for Phase III development.